Dynamk Invests in FloDesign Sonics, Game-Changer for Cell Therapy Production

Englewood Cliffs, NJ, January 10, 2018 - Dynamk Capital, a life sciences venture capital fund, today announced an exciting new investment in advancing the commercial production of CAR T and immunotherapies by adding FloDesign Sonics to its growing portfolio. Dynamk’s portfolio companies provide technologies and services that enable biopharmaceutical companies around the world to develop therapeutics faster and produce them more economically.

Dynamk Capital led the Series A2 round alongside other investors. FloDesign Sonics, a life science company, applies acoustic wave separation to challenges in cell handling.  Acoustic waves have been proven to be able to separate materials based on key characteristics such as size, density, compressibility, and other properties in relation to each other. FloDesign Sonics applies this principle using a device which can separate cells as required as part of the CAR T manufacturing process. This non-invasive, acoustic platform operates as a closed and automated system, addressing challenges of major immunotherapy, cell and gene therapy providers as they seek to scale these critical therapies.

Daniella Kranjac, co-founder and managing director of Dynamk Capital, said, “FloDesign Sonics is fundamentally changing cell selection, handling and separation through application of gentle acoustic processing. We are thrilled to see the commercialization of this technology in bioprocessing, and now FDS is set to innovate cell and gene therapy delivery, reducing cost and improving access to life-saving therapies, by enabling closed, automated, and gentle cell processing.”

FloDesign Sonics’ round was led and comprised by a group of life science leaders and former executives with proven track records, further validating the applications of this broad-reaching technology.  “We are extremely excited to be working with Dynamk Capital and look forward to leveraging the knowledge and experience the team brings. Their unique focus on bioprocessing tools and understanding of what it takes to commercialize products in the space will be a great asset to the future success of FloDesign Sonics.” said Stanley Kowalski, founder and CEO of FloDesign Sonics.

About Dynamk Capital

Dynamk Capital LLC is a venture capital firm investing in early stage life sciences companies.  Dynamk’s investment strategy is centered on identifying companies developing disruptive technologies, tools and services that enable the full biopharma continuum across discovery, development and manufacturing of therapeutics. The Dynamk team includes experienced life science entrepreneurs, investors, advisors and subject matter experts.  Please visit www.dynamk.vc for more information.

About FloDesign Sonics

Founded in 2010, FloDesign Sonics develops acoustic technologies for the separation, concentration and purification of materials in an active fluid.  Their key focus area is cell therapy, helping to address manufacturing challenges related to the processing, separation and purification of CAR T cells. Please visit www.fdsonics.com for more information.  


Media and Investors:
Dynamk Capital LLC

Dynamk Invests in Envisagenics A.I. Drug Discovery

Englewood Cliffs, NJ, November 28, 2017 - Dynamk Capital, a recently launched life sciences venture capital fund, today announced an exciting new investment in early drug discovery by adding Envisagenics, Inc. to its growing portfolio. 

Dynamk Capital invested $500,000 in Envisagenics, leading the $2.25 million seed round alongside other investors. Envisagenics, a life science company applies artificial intelligence to the genetic sequence of patients to discover new therapies.  Its proprietary cloud-based discovery platform SpliceCoreTM uses machine learning to prioritize new drug target candidates from patients’ RNA. 

Daniella Kranjac, co-founder and managing director of Dynamk Capital, said, “Envisagenics is disrupting traditional drug discovery through applied machine learning and AI.  We are excited to see the commercialization of SpliceCore enable biopharma leaders to accelerate critical discovery efforts for life-saving therapeutics.”

Dynamk Capital Announces First Closing

Dynamk Capital Announces First Closing

Dynamk Capital Announces First Closing and Launch of Life Sciences Venture Fund

ENGLEWOOD CLIFFS, NJ, Sept. 26, 2017 /PRNewswire/ -- Dynamk Capital has announced a first close for its venture fund providing early stage capital to innovative companies providing tools, technologies and services within the Life Sciences sector.   The fund is on track for a final close in 2018 and expects to invest in 8-10 companies over the next several years.  Since founding in 2016, Dynamk has been actively cultivating deal flow as well as relationships with limited partners and strategic investors. 

“We are excited about the strong support of the fund at this early stage, especially among leaders in the sector,” said Daniella Kranjac, Managing Partner of Dynamk Capital.  “Investors in our fund will be provided with the opportunity to engage in the discovery and production of life-saving therapies, and ultimately making these medicines more accessible.”  

Daniella Kranjac joins Stevens Institute of Technology Board of Trustees

Daniella Kranjac of Dynamk Consulting LLC and Dynamk Capital Advisors joins the Stevens Institute of Technology Board of Trustees as a charter member.  

About Stevens:  Stevens Institute of Technology, The Innovation University® is a premier, private research university in Hoboken, NJ overlooking the Manhattan skyline.  Stevens is home to three national research centers of excellence, as well as joint research programs focused on innovation in: healthcare & medicine, sustainable energy, financial systems, defense & security and STEM education. 

Make Your Own Ladder

Starting out as a professional, most people thought it was completely crazy to join a startup during the dot-com bubble.  Professors, friends voiced their concern, and family warned about the lack of dental coverage in the startup benefits package!  The fact that most startups fail was looming over my first career steps...   

View original post on LinkedIn